Blog

Using Big Data and AI to return pharma productivity to sustainable levels.

Emerging research approaches and real-world evidence are fulfilling the needs of rare disease patients with increased speed.

RWE is being used to provide a more comprehensive data set for regulators’ and payers’ use in approval and reimbursement decisions.

According to an ICON survey, artificial intelligence (AI) was considered the digital technology with the most potential to improve R&D productivity

Taking into consideration the lessons learned from Alzheimer’s disease studies could benefit the design of neuro-protective studies.

The size and significance of the APAC market make clinical trials, on the cutting edge of oncology development, an attractive investment.

Sites participating in ACT trials need to be prepared with regulatory intelligence, scalable logistics, adequate resources and dedicated data management teams.

Orphan drugs, by nature, remain commercially underdeveloped, and as demand in the market increases, patients in clinical trials need to be considered.

Attempting to develop casual treatment against the progression of Alzheimer’s disease has resulted in unparalleled series of failures for nearly 2 decades of drug development.

As more RWE is generated within the biotech industry, a strategic plan is necessary to maximise revenue.

As the buzz around voice technology increases, our digital team is asked more & more, “What’s the deal with voice assistants? Can we offer this to our clients?”

Various regulatory efforts have been implemented in the last 25-30 years to include the patients’ perspective into drug development.

Read our latest blog post to access insights from inside the 2019 Medical Marketing & Media (MM&M) Awards jury room.

Adopting patient-centric elements into oncology clinical trials has the potential to significantly impact patient recruitment and retention.

Social media and digital technology are providing new opportunities for marketers by facilitating direct interaction with patients and care partners.

Getting more connected with the patient and easing their burden is really making a difference to enrollment rates.

The new MDR/IVDR will go into effect in 2020, greatly increasing the complexity of keeping existing products on the market and introducing new ones.

Exploring machine learning and natural language processing to maximize RWE output using advanced computing.

Key takeaways from the EMA’s second draft guidance on MDR and its impact on combination products.

Despite multiple challenges, RWE clearly has huge potential to inform healthcare stakeholders.